MOTS-c

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, discovered in 2015 for striking metabolic effects in mice, including reversal of diet-induced obesity and restored insulin sensitivity. More than a decade later, that mouse literature has not been tested in a completed human trial: the one registered human study, a Phase 2a trial in prediabetes and obesity, is still recruiting and has reported no results. Everything else on the human side is an association between naturally occurring MOTS-c levels and disease states like obesity and diabetes, not a treatment finding. It has no approved use anywhere and no established human dose.

Ask about MOTS-c

Research snapshot

CategoryCurrent information
Peptide categoryMitochondrial-derived peptide (MDP)
Primary research interestMetabolic homeostasis, insulin sensitivity, exercise physiology
Highest available evidencePublished animal research (mouse); human data limited to observational association studies
Human research availableNo completed interventional trial; one registered trial (NCT07505745) opened enrollment February 2026 and has not reported
Development statusNot in formal pharmaceutical development; sold as a research-use compound
Regulatory statusNo FDA or EMA approval; nomination for FDA 503A/503B bulk-substance safety review was withdrawn by its nominator; listed among substances discussed at a July 2026 FDA Pharmacy Compounding Advisory Committee meeting; named in a draft HHS 503A enforcement-discretion policy published 30 Oct 2026 (not approval)

Technical identity

Technical propertyInformation
Primary nameMOTS-c
Alternative namesMOTS-C, MOTSC, MOTs-C, mitochondrial open reading frame of the 12S rRNA type-c, mitochondrial-derived peptide (MDP)
Peptide sequenceMRWQEMGYIFYPRKLR (as reported in a 2026 analogue-engineering paper working from the original 2015 discovery report; not independently cross-checked against the discovery paper’s own sequence figure)
Amino-acid length16 residues
Molecular formulaC101H152N28O22S2: from a chemical-supplier database listing (ChemicalBook, CAS 1627580-64-6); not confirmed against a peer-reviewed or regulatory source
Molecular weight2174.62 g/mol: same supplier-only sourcing; not independently verified
CAS Registry Number1627580-64-6: supplier-listed; not independently verified
PubChem CIDNot established
Chemical modificationsNone reported; encoded within the mitochondrial 12S rRNA gene, not by nuclear DNA
Peptide classMitochondrial-derived peptide
Primary biological targetProposed folate-cycle/AICAR-like AMPK activation; no confirmed human receptor identified
Developer or originatorDiscovered by Lee, Zeng, Drew et al. (2015); not a pharmaceutical sponsor
Development statusPreclinical/early human; one registered, unreported human trial

What it is

MOTS-c is a 16-amino-acid peptide whose name stands for Mitochondrial Open reading frame of the Twelve-S rRNA type-c. It was first described in 2015 by Lee and colleagues at the University of Southern California, UCLA and the National Institute on Aging, who reported that the peptide is encoded by a short open reading frame sitting inside the mitochondrial 12S rRNA gene, part of mitochondrial DNA rather than the nuclear genome (Lee et al., Cell Metabolism, 2015). That placement mirrors an earlier discovery, humanin, a peptide encoded within the neighboring mitochondrial 16S rRNA gene; MOTS-c was found by extending the same search logic to the 12S rRNA region. Reviews since have grouped MOTS-c with humanin and a family of related peptides called SHLP1 through SHLP6 under the umbrella term “mitochondrial-derived peptides.”

A wild-type sequence for the peptide, Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, has been reported in later work describing an engineered analogue built from that same backbone (Zhang et al., Redox Biology, 2026). That paper was not the original discovery report, so the sequence given here should be understood as carried forward from a secondary source rather than read directly off the 2015 paper’s own figures.

No approved MOTS-c drug exists anywhere, for any indication, in any species. There is no FDA label, no EMA label and no other regulatory monograph. As of this compilation, MOTS-c had entered registered human clinical development for the first time, more than a decade after its discovery, through a single Phase 2a trial that had not yet reported results.

How it works, and where the animal-to-human line falls

The 2015 discovery paper proposed a specific biochemical mechanism: MOTS-c was reported to inhibit the folate cycle and the purine synthesis pathway tethered to it, an effect that led to accumulation of an AMP-like intermediate called AICAR and, downstream of that, activation of AMPK, a central cellular energy sensor (Lee et al., 2015). A same-issue commentary described this plainly as MOTS-c promoting “biosynthesis of an endogenous AMP analog, AICAR,” with AICAR itself already known as a compound that activates AMPK when given directly (Zarse and Ristow, Cell Metabolism, 2015). This mechanism was demonstrated in HEK293 and HeLa human cell lines and in mouse tissue, not in isolated human tissue or in any human trial, and the 2015 paper identified skeletal muscle as the peptide’s primary apparent target organ based on that same preclinical work.

The downstream effects reported for this mechanism are, without exception in the literature reviewed for this entry, animal findings. In mice, MOTS-c treatment was reported to prevent age-related and high-fat-diet-induced insulin resistance, and to prevent diet-induced obesity, relative to untreated control mice (Lee et al., 2015). Later mouse and cell-culture work built out a broader circuit around that finding: a reciprocal relationship between MOTS-c and PGC-1alpha, in which pharmacologic AMPK inhibition or PGC-1alpha knockdown lowered MOTS-c expression in mouse muscle tissue and C2C12 muscle cell culture, while treadmill training raised MOTS-c, PGC-1alpha, GLUT4 and phosphorylated AMPK together in high-fat-diet mice (Yang et al., Biochimica et Biophysica Acta, 2021). A separate group reported that MOTS-c and adiponectin regulate one another through an adiponectin-APPL1-SIRT1-PGC-1alpha chain, again in mice and C2C12 cells, with adiponectin-knockout mice and high-fat-diet mice both showing reduced plasma and muscle MOTS-c (Guo et al., Diabetologia, 2020). A third group reported that MOTS-c prevented palmitic-acid-induced atrophy in cultured mouse myotubes and lowered plasma myostatin in diet-induced-obese mice, acting through a signaling chain from CK2 through PTEN, mTORC2, AKT and FOXO1 (Kumagai et al., American Journal of Physiology, 2021).

A separate strand of mouse and cell-culture work has examined MOTS-c as a stress-response signal rather than a metabolic one. In rat lung ischemia-reperfusion injury and cultured endothelial cells, oxidative stress was reported to trigger a chain of events ending in MOTS-c moving into the cell nucleus, where it bound antioxidant-response-element promoters and reduced oxidative lung damage in the treated rats (Li et al., Redox Biology, 2025). A follow-up paper engineered a modified version of the peptide specifically because native MOTS-c was described, in the researchers’ own words, as having “poor membrane permeability due to its high polarity”, a stated pharmacokinetic limitation for the parent molecule, tested only in mouse lung cells and mice with radiation-induced lung injury, not in humans (Zhang et al., 2026).

A dedicated review of this literature summarized the human-mechanism picture bluntly: no confirmatory human cell or tissue study of any of these pathways, folate-cycle inhibition, the PGC-1alpha loop, the adiponectin axis, the anti-atrophy signaling, or the nuclear stress-response pathway, was located in the sources reviewed for this entry. Every mechanistic claim traces to mouse tissue or to cell lines such as HEK293, HeLa and C2C12, not to human subjects.

What dosage information circulates?

Figures in this table summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Prediabetes / overweight or obesity (registered trial, MOTS-MET)Subcutaneous injectionNot specified in the registry recordNot specified in the registry record12-week treatment periodRegistered but unpublished/recruiting trial (NCT07505745, Hudson Biotech)
General metabolic / longevity and exercise-recovery framingSubcutaneous injectionLow single-digit milligram range per stated doseOnce daily to a few times weeklyOften discussed in on/off cycling patterns; no fixed length reportedCommunity / vendor reported

No completed human dosing study of MOTS-c exists in any form. The one registered trial opened enrollment in February 2026, has not reported results, and its registry entry does not specify an exact dose or injection frequency. Circulating vendor and community figures are therefore being compared not against a lower or higher studied human dose, as is possible for many other peptides, but against the complete absence of one.

Potential benefits and research applications

Metabolic health: insulin sensitivity and obesity prevention

What is being investigated: whether MOTS-c can prevent or reverse diet-induced obesity and insulin resistance. How the effect might occur: proposed inhibition of the folate cycle leading to AMPK activation, a central cellular energy sensor. Evidence: the 2015 discovery paper reported prevention of age-related and high-fat-diet-induced insulin resistance and prevention of diet-induced obesity in treated versus untreated mice. Strength: has been shown in mouse models; has not been established in humans. Limitation: the one registered human trial testing this directly, a Phase 2a study in prediabetes and obesity, is still recruiting and has reported no results, so whether the mouse effect translates to people is entirely unknown.

Exercise capacity and muscle signaling

What is being investigated: whether MOTS-c functions as an “exercise mimetic” or exercise-sensitive myokine that supports muscle metabolism and capacity. How the effect might occur: through a proposed PGC-1alpha and AMPK signaling loop in muscle tissue, and a separate pathway preventing muscle-cell atrophy. Evidence: mouse and cell-culture studies reported improved exercise capacity, weight loss and insulin sensitivity, plus prevention of palmitic-acid-induced muscle atrophy. Strength: has been shown in animal and cell-culture models; has not been established in humans. Limitation: a direct human test found only a non-significant trend in circulating MOTS-c after a bout of endurance exercise, and a review of the area described the human chronic-training evidence as conflicting.

Cellular stress response and organ protection

What is being investigated: whether MOTS-c protects tissue from oxidative and ischemic injury by moving into the cell nucleus and activating antioxidant-response genes. How the effect might occur: a stress-triggered signaling chain ending in MOTS-c binding antioxidant-response-element promoters. Evidence: reduced oxidative lung damage in rats with induced lung ischemia-reperfusion injury, and reduced injury in mice with radiation-induced lung damage using an engineered, more cell-permeable analogue. Strength: has been shown in animal and cell-culture models; has not been established in humans. Limitation: native MOTS-c has been described as having poor membrane permeability, which is why researchers built a modified version for this purpose, and no human injury-protection data exist for either the native peptide or the analogue.

Research evidence

One registered human trial, and it has not reported

A search of ClinicalTrials.gov located exactly one interventional trial in which MOTS-c itself is administered to human participants: NCT07505745, registered under the name “MOTS-MET,” a Phase 2a, randomized, double-blind, placebo-controlled study sponsored by Hudson Biotech. The trial was designed to enroll 120 adults aged 18 to 65 with prediabetes and overweight or obesity, randomized 1:1 to MOTS-c or placebo by subcutaneous injection over a 12-week treatment period, with a further 4-week safety follow-up. Its stated co-primary endpoints are the change from baseline in insulin sensitivity, measured by the Matsuda Index derived from an oral glucose tolerance test, and the incidence of treatment-emergent adverse events through 16 weeks. Secondary endpoints include changes in HbA1c and fasting and post-load glucose, plus testing for anti-drug antibodies. The trial’s status, as retrieved for this entry, was recruiting, at a single site in Shenzhen, China, with a stated study start date of February 2026 and a stated study completion date of May 2028. No results had been posted.

This means there is, at the time of this writing, no completed human interventional study of MOTS-c of any kind, for any purpose. Every claim of a demonstrated effect in a human being, metabolic, exercise-related, anti-aging or otherwise, rests on something other than a finished dosing trial, because no finished dosing trial exists yet.

What exists instead: associations with circulating levels, not treatment outcomes

In the absence of an interventional trial, the human evidence base for MOTS-c consists of studies measuring the peptide’s naturally occurring, or “circulating,” levels in blood or muscle and looking for associations with disease states. These are correlational studies; none of them administered MOTS-c to anyone. A systematic review and meta-analysis pooling six case-control studies and one cross-sectional study, 602 participants in total, found that plasma MOTS-c was lower overall in a combined obesity-and-diabetes group compared with controls, but a subgroup analysis reversed that direction by condition: MOTS-c was significantly higher than controls in people with obesity, and significantly lower than controls in people with type 2 diabetes (Zhou et al., Diabetology and Metabolic Syndrome, 2024). The review’s own authors described monitoring MOTS-c as having “prospects” as a future screening tool, framing it as a hypothesis for further study rather than an established diagnostic or therapeutic fact. That split finding is worth sitting with, because it runs against any simple story in which low MOTS-c is bad and restoring it is the fix; in this pooled dataset, two different metabolic diseases moved circulating MOTS-c in opposite directions.

Other correlational findings, all observational and all in specific patient populations, include: lower serum and muscle MOTS-c in women with polycystic ovary syndrome compared with matched controls, with an inverse correlation to testosterone (Kutuk et al., Scientific Reports, 2026); higher serum MOTS-c in diabetic heart-failure patients taking an SGLT2 inhibitor compared with those not taking one, reported by the study authors as hypothesis-generating rather than as evidence that MOTS-c itself was administered or caused the difference (Asil et al., European Journal of Pharmacology, 2024); and a rise in serum MOTS-c within 24 hours of cardiopulmonary bypass surgery that outperformed traditional markers at predicting subsequent lung injury in one surgical cohort, a prognostic biomarker association, not a treatment finding (Li et al., 2025).

The “exercise mimetic” framing often attached to MOTS-c has been tested directly in humans, and the result is weaker than the mouse literature suggests. In a randomized trial of exercise modality (not of MOTS-c dosing) with thirty healthy adults split across endurance exercise, resistance exercise and a control arm, circulating humanin rose significantly after endurance exercise, while MOTS-c showed only “a trend to increase” that did not reach statistical significance; at rest, plasma MOTS-c was not correlated with fitness markers such as VO2 or muscle mitochondrial DNA copy number (von Walden et al., Journal of Applied Physiology, 2021). A dedicated review of this area concluded that evidence for exercise producing chronic changes in MOTS-c is “conflicting,” explicitly separating the largely consistent mouse findings, improved exercise capacity, weight loss and insulin sensitivity in young and aged mice given MOTS-c, from unresolved human data, and describing MOTS-c as a candidate “exercise-sensitive myokine,” a hypothesis rather than an established human fact (Woodhead and Merry, Biochimica et Biophysica Acta, 2021). A more recent study comparing adults with cerebral palsy to typically developing controls found no meaningful difference in resting MOTS-c between groups and no significant between-group change after a bout of exercise (Horwath et al., Experimental Physiology, 2026).

One further caveat applies to nearly all of the circulating-level studies above. A mass-spectrometry method built specifically to detect MOTS-c in doping-control samples found that endogenous MOTS-c levels measured by a commonly used immunoassay could not be confirmed by the more specific liquid-chromatography method, documenting an assay-discordance problem between ELISA-based measurement and mass spectrometry (Knoop, Thomas and Thevis, Rapid Communications in Mass Spectrometry, 2019). Most of the human correlational studies cited above, including the polycystic-ovary-syndrome and heart-failure findings, relied on immunoassay methods of the kind this paper found could not be confirmed against a more specific technique. That does not necessarily invalidate comparisons made within a single study using one consistent assay, but it is a reason to treat any absolute circulating-MOTS-c number, cited anywhere, with some caution.

Safety

Human safety data for MOTS-c are not thin; they are essentially absent, because no human interventional trial has completed. The one registered trial, NCT07505745, was designed to generate the first such data, listing the incidence of treatment-emergent adverse events through 16 weeks as a co-primary endpoint alongside vital signs, ECG, standard laboratory panels and testing for anti-drug antibodies as secondary safety measures. None of that data existed at the time of this compilation, because the trial had not reported.

No dedicated animal toxicology study, such as a repeat-dose or GLP toxicology study, was located for MOTS-c. The mouse studies described in the mechanism and evidence sections above reported metabolic and cell-signaling effects, not formal toxicology endpoints such as organ histopathology or hematology panels. No human pharmacokinetic study exists for MOTS-c; the only pharmacokinetic-adjacent fact identified is that native MOTS-c has been described in the literature as having poor membrane permeability due to its polarity, a cell-uptake observation rather than a measured half-life or clearance value in any species. No serum half-life figure, in animals or humans, was identified in the sources reviewed. Anti-drug antibody testing was written into NCT07505745’s endpoints, which suggests the trial’s sponsor anticipated immunogenicity as an open question, consistent with immunogenicity being a documented issue for other injectable peptides; no MOTS-c-specific immunogenicity data exists yet either way.

Regulatory status

MOTS-c has no approved indication anywhere and no regulatory label of any kind. It has, however, drawn specific regulatory and anti-doping attention distinct from most unapproved research peptides. In the FDA’s review of substances nominated for its Category 2 “Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks” list, MOTS-c was among a group of peptides listed as withdrawn from consideration by whoever had nominated it for that review, a specific administrative status meaning the nomination was withdrawn, not that the substance was found safe or unsafe. A Federal Register notice for the FDA’s Pharmacy Compounding Advisory Committee meeting held in July 2026 listed “MOTs-C (free base and acetate each)” among substances scheduled for committee discussion, alongside several other unapproved research peptides, indicating MOTS-c was under active regulatory consideration for compounding status at that time.

On 28 October 2026 HHS announced a draft enforcement discretion policy for compounding certain peptides under section 503A. It was published in the Federal Register on 30 October 2026 (91 FR 68526, docket HHS-OASH-2026-0496). MOTS-c is one of six peptides named, listed as MOTS-c acetate, with subcutaneous or intramuscular use as the routes in its Appendix B. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding it under 503A if conditions are met. These include a patient-specific prescription, one active ingredient per product, an ingredient from an FDA-registered CGMP manufacturer with a certificate of analysis showing the facility location, adverse event reporting, and the label “This is a compounded drug product. Not for resale.” For safety support the notice cites “a randomized placebo-controlled trial of a MOTS-c analogue” and rodent studies. An analogue is a different molecule, and this entry found no completed trial of MOTS-c itself. It is a draft and is not binding on HHS or the public. It is not an FDA approval, it does not add MOTS-c to the 503A bulks list, and it is not a rule. It does not bind state boards of pharmacy. HHS says it stays in place until each peptide is addressed in a final rule, and it can be withdrawn. It does not cover 503B outsourcing facilities. Comments close 13 November 2026. The evidence assessment on this page is unchanged. The full analysis of the HHS policy covers all six peptides. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.

On the anti-doping side, two dedicated papers have treated MOTS-c as a substance of interest well before any human trial existed. A 2016 survey of emerging performance-enhancement threats listed MOTS-c, by way of its folate-cycle and AMPK-activating mechanism, among compounds “necessitating preventive and proactive anti-doping measures,” in the same category as direct AMPK activators and PPAR-delta agonists (Thevis and Schanzer, Rapid Communications in Mass Spectrometry, 2016). A 2019 paper built and validated, to World Anti-Doping Agency standards, a mass-spectrometry assay specifically to detect synthetic MOTS-c in doping-control plasma samples, concluding that it appeared advisable to monitor potential use of synthetic MOTS-c in sport (Knoop, Thomas and Thevis, 2019). The precise section of the current World Anti-Doping Agency Prohibited List under which MOTS-c is formally categorized was not independently confirmed for this entry.

The mouse-to-human gap

The honest summary of MOTS-c, more than a decade after its discovery, is a large and mechanistically detailed mouse and cell-culture literature sitting on one side of a line, and almost nothing on the other. The mouse findings are not modest: reversal of diet-induced obesity, restoration of insulin sensitivity, improved exercise capacity, prevention of muscle atrophy and reduced organ damage in injury models have all been reported in mice or in cultured cells. None of that has been tested against a placebo in a completed human trial. The single registered human study opened enrollment in February 2026 and, as of this compilation, had reported no results. Everything else on the human side is an association between naturally occurring MOTS-c levels and a disease state, obesity, type 2 diabetes, polycystic ovary syndrome, heart failure, measured with an assay method that a validation study found does not agree with a more specific mass-spectrometry technique. No human dose has ever been established as safe or effective for any purpose, because no completed human dosing study exists to establish one.

That gap is worth stating without softening, because MOTS-c is already being discussed, and sold, in a research-peptide and longevity market years ahead of any human outcome data telling anyone whether the mouse effects translate at all. For most peptides in this kind of survey, the tension is between a narrow approved use and a much broader circulating one. For MOTS-c, the tension is more basic than that: it is the difference between a striking animal literature and a human record that, to date, amounts to one recruiting trial and a handful of correlational studies that were never designed to test whether giving a person MOTS-c does anything at all.

Frequently asked questions

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, discovered in 2015. It has no approved use anywhere and no completed human trial.

How does it work?

In mice, it is proposed to inhibit the folate cycle, activating AMPK, a cellular energy sensor, which drives downstream effects on insulin sensitivity and fat metabolism. No human cell or tissue study of this mechanism was located.

What dosage has been studied?

No dose has been established as safe or effective for any use. The one registered human trial, a Phase 2a study, does not disclose an exact dose or injection frequency in its public registry record, and it has not reported results.

What dosage commonly circulates online?

Vendor material commonly describes low single-digit-milligram vials, dosed by subcutaneous injection roughly once daily to a few times weekly in on/off cycles. There is no completed human dosing study of any kind to check these figures against.

Has it been studied in humans?

Not in a completed interventional trial. The only human data are correlational studies measuring naturally occurring MOTS-c levels and associating them with conditions like obesity, type 2 diabetes and PCOS.

Does it really work as an exercise mimetic?

That has not been established in humans. A direct test found only a non-significant trend in MOTS-c after endurance exercise, and a review called the human chronic-training evidence conflicting, in contrast to a consistent mouse literature.

What side effects have been reported?

None have been formally documented in humans, because no completed human trial exists. The one registered trial was designed to generate the first such safety data.

Is it approved?

No. It has no FDA or EMA approval anywhere, though it has drawn specific FDA compounding-committee and anti-doping attention.

What remains unknown?

Nearly everything about how MOTS-c behaves in a human body: whether the mouse metabolic and exercise effects translate to people, what a safe and effective human dose would be, and even whether higher or lower circulating MOTS-c is the better state, since it moves in opposite directions in obesity and type 2 diabetes.

Bottom line

MOTS-c has a striking, mechanistically detailed mouse and cell-culture literature: reversal of diet-induced obesity, restored insulin sensitivity, improved exercise capacity and reduced organ injury have all been reported in animals. None of that has been tested against a placebo in a completed human trial. The single registered human study opened enrollment in 2026 and has reported no results. What exists on the human side instead is a set of correlational studies linking naturally occurring MOTS-c levels to disease states, measured with an assay method a validation study found does not agree with a more specific technique. No human dose has ever been established as safe or effective for any purpose.

Related entries: AOD-9604, a fragment of growth hormone.

Reported amounts and the evidence behind them: MOTS-c dosage: human data, mouse doses and online schedules.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
General metabolic / longevity and exercise-recovery framingSubcutaneous injectionLow single-digit milligram range per stated doseOnce daily to a few times weeklyOften discussed in on/off cycling patterns; no fixed length reported

Research-peptide vendor material commonly presents MOTS-c as lyophilized powder in vials in the low single-digit-milligram range, dosed by subcutaneous injection at a stated frequency of roughly once daily to a few times weekly, often discussed in "on" and "off" cycles and framed around exercise, metabolic and longevity use drawn from the mouse literature above. This pattern reflects general knowledge of how the research-peptide market presents compounds and was not checked against any specific vendor site or listing in the course of compiling this entry; no site is named and no figure is dated, and none should be read as verified. The comparison that matters here is unusually stark: these figures circulate for a compound with zero completed human dosing studies of any kind. There is no human trial, published or unpublished, against which a circulating dose can be checked, because none has finished. Every circulating figure for MOTS-c is therefore being compared not against a lower or higher studied dose, as is possible for many other compounds, but against the complete absence of a studied human dose.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Sources

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. Discovery paper; folate-cycle/AICAR/AMPK mechanism and mouse obesity/insulin-resistance findings, cell-line and mouse data only. PMID 25738459
  2. Zarse K, Ristow M. A mitochondrially encoded hormone ameliorates obesity and insulin resistance. Cell Metabolism. 2015;21(3):355-356. Same-issue commentary describing the AICAR/AMPK mechanism. PMID 25738453
  3. Zhang et al. Engineered R13A-MOTS-c analogue for improved cell permeability; mouse lung cell and radiation-injury mouse data; source of the sequence given in this entry and of the "poor membrane permeability" description of native MOTS-c. PMID 42142418
  4. Yang et al. AMPK/PGC-1alpha/MOTS-c reciprocal signaling in C2C12 mouse myotubes and high-fat-diet mice; treadmill training effects on MOTS-c expression. PMID 33722744
  5. Guo et al. Adiponectin-APPL1-SIRT1-PGC-1alpha-MOTS-c axis in wild-type and adiponectin-knockout mice and C2C12 cells. PMID 32880686
  6. Kumagai et al. MOTS-c and anti-atrophy/myostatin signaling in C2C12 myotubes and diet-induced-obese mice; also reports a human correlational MOTS-c/myostatin association. PMID 33554779
  7. Li et al. MOTS-c nuclear translocation and Nrf2/antioxidant-response-element activation in rat lung ischemia-reperfusion injury and endothelial cell culture; embedded human biomarker finding predicting post-cardiopulmonary-bypass ARDS. PMID 40403491
  8. Zhou et al. Systematic review and meta-analysis of circulating MOTS-c across metabolic states; 602 participants; MOTS-c elevated in obesity, reduced in type 2 diabetes. PMID 39160573
  9. Kutuk et al. Case-control study of serum and muscle MOTS-c in polycystic ovary syndrome versus matched controls. PMID 41680431
  10. Asil et al. Serum MOTS-c in diabetic HFrEF patients on SGLT2 inhibitors versus not, and versus healthy controls; hypothesis-generating, no MOTS-c administered. PMID 39182552
  11. von Walden et al. Randomized trial of exercise modality in 30 healthy adults; circulating MOTS-c and humanin response to acute endurance and resistance exercise. PMID 34351816
  12. Woodhead, Merry. Review characterizing mouse MOTS-c exercise-capacity literature and describing human chronic-training evidence as conflicting. PMID 34520826
  13. Horwath et al. Resting and post-exercise circulating MOTS-c, humanin and SHMOOSE in adults with cerebral palsy versus typically developing controls. PMID 42349896
  14. Knoop, Thomas, Thevis. WADA-validated LC-MS/MS assay for MOTS-c in doping-control plasma; documents discordance between ELISA and mass-spectrometry measurement of endogenous MOTS-c. PMID 30394592
  15. Thevis, Schanzer. Survey of emerging doping threats listing MOTS-c among compounds requiring proactive anti-doping measures. PMID 26842585
  16. A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c in Adults With Prediabetes and Overweight/Obesity. Status: recruiting. No results posted. NCT07505745

Live registry status

These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.

TrialPhaseStatusSponsorEnrolledPrimary completionRegistry updated
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
NCT07505745
Phase 2RecruitingHudson Biotech120Feb 14, 2027Apr 1, 2026

Open these in the trial tracker

Share thisFacebookXEmail